Breaking News: PFE – Market Insights, Analysis & Latest Updates

HLN
PFE

Pfizer offloads $3.3 billion stake in Sensodyne-maker Haleon

Pfizer sold $3.26 billion in Haleon shares, reducing its stake to 15% in the largest standalone consumer healthcare firm.

investing.com • 01/10/2024 - 06:14 AM

HLN
PFE

Pfizer to offload about 6% stake in Sensodyne-maker Haleon, says bookrunner

Pfizer plans to sell 540 million shares of Haleon, reducing its stake to 16.2%. Haleon will buy 230 million pounds of its shares from Pfizer.

investing.com • 30/09/2024 - 16:19 PM

Why gene therapy for sickle cell is slow to catch on with patients

Zoe Davis, a sickle cell patient, hesitates to try new gene therapies due to their novelty and costs. Many patients face similar challenges, impacting treatment uptake.

investing.com • 28/09/2024 - 10:22 AM

Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say

Pfizer's withdrawal of sickle cell treatment Oxbryta due to death risks may accelerate trials for rival drugs and leaves many patients relying on older treatments like hydroxyurea.

investing.com • 26/09/2024 - 15:39 PM

PFE

EU regulator recommends suspension of Pfizer's sickle cell disease treatment

EMA recommended suspending Oxbryta's authorization due to safety concerns. Pfizer plans to withdraw the drug from approved markets, citing associated risks.

investing.com • 26/09/2024 - 15:13 PM

PFE

Slow progress on Pfizer's plan to sell drugs to low-income nations at not-for-profit price, says CEO

Pfizer's program for affordable medicines in low-income countries has seen slow uptake, with bureaucracy and competing crises hindering progress despite ongoing talks with additional nations.

investing.com • 26/09/2024 - 11:25 AM

PFE

Pfizer withdraws sickle cell disease treatment on risk of complication, death

Pfizer is withdrawing its sickle cell treatment Oxbryta due to safety concerns, including complications and deaths, following a review of clinical data.

investing.com • 25/09/2024 - 21:17 PM

US will still pay at least twice as much after negotiating drug prices

The U.S. negotiated drug prices under Medicare remain significantly higher than those in other wealthy nations, highlighting disparities in healthcare costs and market dynamics.

investing.com • 03/09/2024 - 10:07 AM

PFE
SNY

Delaware top court will hear drugmakers' appeal to end Zantac lawsuits

Delaware's highest court will hear an appeal from GSK and others to end lawsuits alleging cancer risk from Zantac, as plaintiffs may present expert testimony on the matter.

investing.com • 27/08/2024 - 19:03 PM

Currency